Así, los investigadores llegan a la siguiente conclusión: "Se observa neuroinflamación en amplias áreas del cerebro de los enfermos de SFC/EM, correlacionada con la severidad de los síntomas neuropsicológicos. La evaluación de la neuroinflamación en los enfermos de SFC/EM puede ser esencial para entender la patofisiología básica y para el desarrollo de criterios diagnósticos objetivos y tratamientos médicos eficaces"
Seguimos avanzando en la dirección correcta!
[t]Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An 11C-(R)-PK11195 PET Study[/t]
Yasuhito Nakatomi1,2, Kei Mizuno2–4, Akira Ishii2,3, Yasuhiro Wada2,3, Masaaki Tanaka2,3, Shusaku Tazawa2,3, Kayo Onoe2, Sanae Fukuda2,3, Joji Kawabe5, Kazuhiro Takahashi2,3, Yosky Kataoka2,3, Susumu Shiomi5, Kouzi Yamaguti3, Masaaki Inaba1, Hirohiko Kuratsune3,6,7 and Yasuyoshi Watanabe2,3
+ Author Affiliations
1Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
2RIKEN Center for Life Science Technologies, Hyogo, Japan
3Department of Physiology, Osaka City University Graduate School of Medicine, Osaka, Japan
4Department of Medical Science on Fatigue, Osaka City University Graduate School of Medicine, Osaka, Japan
5Department of Nuclear Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan
6Department of Health Science, Kansai University of Welfare Sciences, Osaka, Japan; and
7Graduate School of Agricultural and Life Sciences, University of Tokyo, Tokyo, Japan
For correspondence or reprints contact: Yasuyoshi Watanabe, RIKEN Center for Life Science Technologies, 6-7-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan. E-mail: [email protected]
Abstract
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a disease characterized by chronic, profound, disabling, and unexplained fatigue. Although it is hypothesized that brain inflammation is involved in the pathophysiology of CFS/ME, there is no direct evidence of neuroinflammation in patients with CFS/ME.
Activation of microglia or astrocytes is related to neuroinflammation. 11C-(R)-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline-carboxamide (11C-(R)-PK11195) is a ligand of PET for a translocator protein that is expressed by activated microglia or astrocytes.
We used 11C-(R)-PK11195 and PET to investigate the existence of neuroinflammation in CFS/ME patients.
Methods: Nine CFS/ME patients and 10 healthy controls underwent 11C-(R)-PK11195 PET and completed questionnaires about fatigue, fatigue sensation, cognitive impairments, pain, and depression. To measure the density of translocator protein, nondisplaceable binding potential (BPND) values were determined using linear graphical analysis with the cerebellum as a reference region. Results: The BPND values of 11C-(R)-PK11195 in the cingulate cortex, hippocampus, amygdala, thalamus, midbrain, and pons were 45%–199% higher in CFS/ME patients than in healthy controls.
In CFS/ME patients, the BPND values of 11C-(R)-PK11195 in the amygdala, thalamus, and midbrain positively correlated with cognitive impairment score, the BPND values in the cingulate cortex and thalamus positively correlated with pain score, and the BPND value in the hippocampus positively correlated with depression score.
Conclusion: Neuroinflammation is present in widespread brain areas in CFS/ME patients and was associated with the severity of neuropsychologic symptoms. Evaluation of neuroinflammation in CFS/ME patients may be essential for understanding the core pathophysiology and for developing objective diagnostic criteria and effective medical treatments.
enlace: http://jnm.snmjournals.org/content/earl ... 113.131045" onclick="window.open(this.href);return false;
